• Zealand Pharma reported positive topline Phase 2 results for weekly petrelintide in overweight or obese adults with type 2 diabetes.
• The study met its main goal, showing meaningful weight loss and improved blood-sugar control versus placebo.
• Safety looked consistent with earlier testing, with few treatment stops tied to gastrointestinal side effects.
• Full trial results will be presented at a future scientific conference.
• A Phase 3a program with Roche has started, targeting about 7,000 participants across three registrational trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610071313OMX_____CNEWS_EN_GNW1001276830_en) on October 07, 2026, and is solely responsible for the information contained therein.